I recently joined the register and I am already very impressed with Michael and the team’s incremental and forward momentum which is laying the groundwork for a great future for patients and investors. The company didn’t just outsource the drug manufacturing but appointing someone with a high calibre to ensure proper process and quality to take it all the way to marketing approval. Even if we license this drug to another pharma for distribution we could control the manufacturing and hence keep a higher proportion of the pie vs just getting royalties on sales.
This also indicates to me that the company is prep for a long game instead of a quick M&A.
No advice. AIMO.
I recently joined the register and I am already very impressed...
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.020(8.89%) |
Mkt cap ! $81.16M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.5¢ | $331.9K | 1.617M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 440882 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 12736 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |